XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Kurt A JenkinsMiso ParkMagali Pederzoli-RibeilUgur EskiocakParker JohnsonWilson GuzmanMegan McLaughlinDeborah Moore-LaiCaitlin O'TooleZhen LiuBenjamin NicholsonVeronica FleschHuawei QiuTim ClacksonRonan C O'HaganUlrich RodeckMargaret KarowJennifer O'NeilJohn C WilliamsPublished in: Journal for immunotherapy of cancer (2023)
These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.